- Home
- CGAU vs KNSA Comparison
CGAU vs KNSA Comparison
Compare CGAU & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- KNSA
- Stock Information
- Founded
- CGAU 2002
- KNSA 2015
- Country
- CGAU Canada
- KNSA United Kingdom
- Employees
- CGAU N/A
- KNSA N/A
- Industry
- CGAU Precious Metals
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- CGAU Basic Materials
- KNSA Health Care
- Exchange
- CGAU Nasdaq
- KNSA Nasdaq
- Market Cap
- CGAU 1.2B
- KNSA 1.4B
- IPO Year
- CGAU N/A
- KNSA 2018
- Fundamental
- Price
- CGAU $6.17
- KNSA $20.02
- Analyst Decision
- CGAU Buy
- KNSA Strong Buy
- Analyst Count
- CGAU 2
- KNSA 5
- Target Price
- CGAU $11.00
- KNSA $36.60
- AVG Volume (30 Days)
- CGAU 676.4K
- KNSA 549.0K
- Earning Date
- CGAU 02-20-2025
- KNSA 02-25-2025
- Dividend Yield
- CGAU 3.29%
- KNSA N/A
- EPS Growth
- CGAU N/A
- KNSA N/A
- EPS
- CGAU 0.47
- KNSA N/A
- Revenue
- CGAU $1,252,073,000.00
- KNSA $384,098,000.00
- Revenue This Year
- CGAU $15.44
- KNSA $60.10
- Revenue Next Year
- CGAU N/A
- KNSA $34.22
- P/E Ratio
- CGAU $13.05
- KNSA N/A
- Revenue Growth
- CGAU 29.99
- KNSA 54.41
- 52 Week Low
- CGAU $4.88
- KNSA $16.56
- 52 Week High
- CGAU $7.82
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- CGAU 45.08
- KNSA 53.15
- Support Level
- CGAU $6.32
- KNSA $19.31
- Resistance Level
- CGAU $6.94
- KNSA $20.20
- Average True Range (ATR)
- CGAU 0.25
- KNSA 0.80
- MACD
- CGAU -0.05
- KNSA 0.06
- Stochastic Oscillator
- CGAU 2.44
- KNSA 72.80
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets worldwide. The company manages its reportable operating segments by a combination of geographic location and products. The Kyrgyz Republic segment includes the operations of the Kumtor Gold Project. The Turkish segment represents the development of the OksUt Project. The North America Gold- Copper segment represents the operations of the Mount Milligan Mine. The North America Molybdenum segment includes the operations of the Langeloth processing facility and the care and maintenance activities of the Endako and Thompson Creek Mines.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.